AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNTI
  4. [8-K] Senti Biosciences, Inc. Reports Material Event

[8-K] Senti Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock SNTI logo
Senti Bioscience

NASDAQ:SNTI

SNTI Rankings

#8018 Ranked by Market Cap
N/A Ranked by Dividends

SNTI Latest News

Aug 7, 2025
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Aug 5, 2025
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Jul 22, 2025
Senti Biosciences Participates in the Virtual Investor 鈥淲hat鈥檚 Your Story鈥� Summer Spotlight On-Demand Conference
Jul 21, 2025
Senti Bio鈥檚 Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
Jul 18, 2025
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

SNTI Latest SEC Filings

Aug 7, 2025
[10-Q] Senti Biosciences, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Senti Biosciences, Inc. Reports Material Event
Jul 21, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity
Jul 21, 2025
[Form 3] Senti Biosciences, Inc. Initial Statement of Beneficial Ownership
Jun 30, 2025
[8-K] Senti Biosciences, Inc. Reports Material Event

SNTI Stock Data

44.08M
11.16M
57.21%
28.21%
2.51%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO